

FEB 25 2005

Atty Docket No. 082377-000000US

PTO FAX NO.: 703-872-9306

ATTENTION: Examiner Chernyshev, Olga N.

Group Art Unit 1646

OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Chernyshev, Olga N.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of Nishimoto, I., Application No. 10/088,724, filed June 14, 2002 for HUMANIN, A POLYPEPTIDE SUPPRESSING NEURONAL DEATH are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Transmittal (1 page)
2. Response to Non-Compliant Amendment (3 pages)
3. Replacement Drawings (4 sheets)

Number of pages being transmitted, including this page: 9

Dated: 2/25/05


Shemekia N. Brown

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**


TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 650-326-2400
Fax: 650-326-2422


60420597 v1

PTO/SB/21 (09-04)

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/088,724	
	Filing Date	June 14, 2002	
	First Named Inventor	NISHIMOTO, Ikuo	
	Art Unit	1646	
	Examiner Name	Chernyshev, Olga N.	
Total Number of Pages in This Submission	8	Attorney Docket Number	082377-000000US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavit(s)/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input checked="" type="checkbox"/> Replacement Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Joel M. Harris		
Date	2/25/05	Reg. No.	44,743

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. (703) 872-9308 on 02/25/05.			
Signature			
Typed or printed name	Shemekia N. Brown	Date	02/25/05

60430885 v1

FEB 25 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nishimoto, I.

Application No.: 10/088,724

Filed: June 14, 2002

For: HUMANIN, A POLYPEPTIDE
SUPPRESSING NEURONAL DEATH

□

Customer No.: 20350

Confirmation No. 6929

Examiner: Chernyshev, Olga N.

Technology Center/Art Unit: 1646

RESPONSE TO NON-COMPLIANT
AMENDMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed 02/04/05, please enter the following
amendments and remarks.

Amendments to the Drawings begin on page 2 of this paper and include both an attached
replacement sheet and an annotated sheet showing changes.

Remarks/Arguments begin on page 3 of this paper.